Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8) - The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects - The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Toll Like Receptor 8 (CD288 or TLR8) Overview 7 Therapeutics Development 8 Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Stage of Development 8 Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Therapy Area 9 Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Indication 10 Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Companies 14 Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development 24 3M Drug Delivery Systems 24 Foamix Pharmaceuticals Ltd. 25 Folia Biotech Inc. 26 Galderma S.A. 27 Idera Pharmaceuticals, Inc. 28 MedImmune, LLC 29 Merck & Co., Inc. 30 Resolve Therapeutics, LLC 31 VentiRx Pharmaceuticals, Inc. 32 Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles 33 854-A - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Drug 1 to Agonize TLR7 and TLR8 for Oncology - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Drug 2 to Agonize TLR7 and TLR8 for Oncology - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Drug to Agonize TLR7 and TLR8 for Oncology - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 imiquimod - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 IMO-8400 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 IMO-9200 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 JB-6121 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 leishmaniasis vaccine - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 MEDI-9197 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 motolimod - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 resiquimod - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 RSLV-132 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 VTX-1463 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 VTX-294 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Toll Like Receptor 8 (CD288 or TLR8) - Dormant Projects 59 Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products 60 Toll Like Receptor 8 (CD288 or TLR8) - Featured News & Press Releases 61 May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference 61 Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study 61 Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia 62 Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 63 Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom's Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting 64 May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors 64 Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer 66 Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma 66 Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia 67 Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting 67 Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings 69 Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 70 Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy 70 Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 71 Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis 72 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 23 Pipeline by 3M Drug Delivery Systems, H2 2016 24 Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 25 Pipeline by Folia Biotech Inc., H2 2016 26 Pipeline by Galderma S.A., H2 2016 27 Pipeline by Idera Pharmaceuticals, Inc., H2 2016 28 Pipeline by MedImmune, LLC, H2 2016 29 Pipeline by Merck & Co., Inc., H2 2016 30 Pipeline by Resolve Therapeutics, LLC, H2 2016 31 Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 32 Dormant Projects, H2 2016 59 Discontinued Products, H2 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
